Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 42 of 42 entries
View as:

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Phase: N/A Priority: Normal
NCT ID: NCT04827719 Org: User:
Start: 05/01/21 End: 01/13/25 Due: 01/13/26

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03503409 Org: User:
Start: 05/14/19 End: 04/02/27 Due: 04/02/28

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT01324960 Org: User:
Start: 03/31/11 End: 12/31/14 Due: 12/31/15

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Phase: N/A Priority: Normal
NCT ID: NCT00424229 Org: User:
Start: 10/31/06 End: 10/31/08 Due: 10/31/09

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure

Phase: N/A Priority: Normal
NCT ID: NCT01748240 Org: User:
Start: 03/31/13 End: 07/31/15 Due: 07/31/16

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Phase: N/A Priority: Normal
NCT ID: NCT01088373 Org: User:
Start: 03/25/10 End: 07/25/16 Due: 07/25/17

Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT02428686 Org: User:
Start: 06/30/10 End: 03/31/14 Due: 03/31/15

Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

Phase: N/A Priority: Normal
NCT ID: NCT01098084 Org: User:
Start: 11/30/08 End: 06/30/09 Due: 06/30/10

Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06956755 Org: User:
Start: 07/07/03 End: 01/05/31 Due: 01/05/32

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

Phase: N/A Priority: Normal
NCT ID: NCT05768711 Org: User:
Start: 10/04/23 End: 10/31/28 Due: 10/31/29

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Phase: N/A Priority: Normal
NCT ID: NCT05181735 Org: User:
Start: 05/18/22 End: 06/19/29 Due: 06/19/30

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

Phase: N/A Priority: Normal
NCT ID: NCT02214407 Org: User:
Start: 10/14/14 End: 08/16/21 Due: 08/16/22

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03744390 Org: User:
Start: 04/02/19 End: 03/18/26 Due: 03/18/27

Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

Phase: N/A Priority: Normal
NCT ID: NCT00437450 Org: User:
Start: 10/31/04 End: 09/30/05 Due: 09/30/06

Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT01063257 Org: User:
Start: 04/30/10 End: 03/31/14 Due: 03/31/15

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT05782127 Org: User:
Start: 12/06/23 End: 11/30/28 Due: 11/30/29

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Phase: N/A Priority: Normal
NCT ID: NCT03588078 Org: User:
Start: 09/15/18 End: 05/15/21 Due: 05/15/22